|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||177.90 - 181.60|
|52 Week Range||127.67 - 181.60|
|PE Ratio (TTM)||204.19|
|Earnings Date||Jul 25, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||191.45|
Vertex Pharmaceuticals Incorporated (VRTX) will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close. An archived webcast will be available on the company's website. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7. After Gemphire announced positive clinical trial results on June 28, its stock price started to rise and closed at $5.24, and on June 29, it rose ~94.47% to $10.19.
According to Incyte Corporation (INCY), the firm is a “Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.”
Ionis Pharmaceuticals (IONS), an RNA1-targeted therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies. In Q1 2018, Ionis’s revenue grew 24.7% YoY (year-over-year) to $144.4 million from $115.8 million.
In June, Health Canada approved Vertex Pharmaceuticals’ (VRTX) Symdeko for the treatment of the underlying cause of cystic fibrosis in individuals over 12 years old who have two copies of the F508del mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene or who have one copy of the F508del mutation and one mutation in another CFTR gene. Health Canada’s approval of Symdeko was based on data from the Phase 3 EVOLVE and EXPAND trials, which enrolled 744 individuals over 12 years old with cystic fibrosis and with two copies of the F508del mutation or one F508del mutation and another mutation assumed to be responsive to tezacaftor/ivacaftor.
Vertex Pharmaceuticals (VRTX) generated net revenue of $638 million from the sales of cystic fibrosis products in the first quarter, reflecting ~33% YoY (year-over-year) growth.
In the week that ended on June 29, Vertex Pharmaceuticals (VRTX) stock closed at $169.96, which represented a ~7% rise from its previous week’s close of $159.76. On June 29, Vertex Pharmaceuticals’ stock price rose 15.16% to reach $169.96 from its previous day’s close of $147.59. In June, Vertex Pharmaceuticals announced that its cystic fibrosis drug Orkambi would be reimbursed in Sweden.
Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.
NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Acceleron Pharma and Vertex Pharmaceuticals both saw big gains on Friday on separate positive catalysts last week. Acceleron and Celgene reported strong results ...
Vertex Pharmaceuticals (VRTX) stock rose on June 29 after peer Galapagos (GLPG) announced mediocre mid-stage study data for its cystic fibrosis drug. Galapagos also announced that its potential development collaboration with AbbVie (ABBV) for a different triple combination therapy for cystic fibrosis is most likely being dropped, as AbbVie pulled out of the talks.
Stocks added to Thursday's gains to end the quarter on a high note, with the Dow Jones Industrial Average up 0.2%. The Dow Jones Industrial Average rose 55.36 points, or 0.2%, to 24.271.41. The Nasdaq Composite, which escaped some of the trade war turmoil, takes the cake however: It 0.1% to 7510.30 today, but it's up 6.3% this quarter and has jumped 8.8% since the start of 2018. Global stocks had their worst start to the year since 2010, but the fact that all three major indexes managed to notch gains for the second quarter seems like a feat, given the near-constant worry about tariffs that repeatedly torpedoed the market of late.
Vertex Pharmaceuticals shares rocketed to a three-month high Friday after rival Galapagos released disappointing for a cystic fibrosis treatment.
released mediocre mid-stage test results for its new cystic fibrosis drug Friday. Shares for the Boston-based Vertex rose $20.78 -- 14.1% -- to $168.49 on the news that Galapagos' FEV-1 improvements in its Phase II trial came in below Wall Street's expectations. Galapagos, meanwhile, fell $4.29 -- 4.48% -- $91.52 in mid-afternoon trading as the company also announced that its possible collaboration with AbbVie Inc.
A positive reading on May consumer spending data, bank stress tests and Nike earnings results put a positive spin on the start of final session of June, and of the second quarter.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...
Stock futures gained premarket strength Friday, as banks rallied and Nike and KB Home posted strong gains, but investors were eyeing China's markets and personal spending data due early Friday.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that Health Canada approved PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, or who have one copy of the F508del mutation and one of the following mutations in the CFTR gene: P67L, D110H, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T. “This approval is an important milestone in our journey to enhance and expand treatment options for people living with CF,” said Reshma Kewalramani, M.D., Executive Vice President and Chief Medical Officer at Vertex.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. Over the last one-month, outflows of investor capital in ETFs holding VRTX totaled $1.59 billion.
The company is the name behind a large collection of 3D modeling and computer-aided drafting platforms — most of which are sold on a subscription basis. Who know cloud-based drafting software could help create one of the market’s top fast-growing stocks?